IL-23 selectively promotes the metastasis of colorectal carcinoma cells with impaired Socs3 expression via the STAT5 pathway

Carcinogenesis

Volumn 35, Issue 6, 2014, Pages 1330-1340

  Zhang, Le ^a   Li, Jun ^a   Li, Li ^b   Zhang, Jie ^a   Wang, Xiaodong ^b   Yang, Chuanhua ^b   Li, Yanyan ^a   Lan, Feng ^a   Lin, Ping ^a  

^a SICHUAN UNIVERSITY   (China)

^b SICHUAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

DNA METHYLTRANSFERASE 1; INTERLEUKIN 23; STAT5 PROTEIN; SUPPRESSOR OF CYTOKINE SIGNALING 3; DNA (CYTOSINE 5 ) METHYLTRANSFERASE 1; DNA (CYTOSINE 5) METHYLTRANSFERASE; DNA (CYTOSINE-5-)-METHYLTRANSFERASE 1; SOCS3 PROTEIN, HUMAN; SUPPRESSOR OF CYTOKINE SIGNALING;

ARTICLE; CANCER CELL LINE; CANCER PATIENT; COLORECTAL CARCINOMA; DISEASE ASSOCIATION; DNA METHYLATION; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION; HCT116 CELL LINE; HT 29 CELL LINE; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; METASTASIS; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; SW 480 CELL LINE; SW 620 CELL LINE; WESTERN BLOTTING; ANIMAL; CELL MOTION; COLORECTAL TUMOR; DISEASE MODEL; DRUG EFFECT; GENETICS; MALE; METABOLISM; MOUSE; PATHOLOGY; PHOSPHORYLATION; TUMOR CELL LINE;

ANIMALS; CELL LINE, TUMOR; CELL MOVEMENT; COLORECTAL NEOPLASMS; DISEASE MODELS, ANIMAL; DNA (CYTOSINE-5-)-METHYLTRANSFERASE; DNA METHYLATION; GENE EXPRESSION; HUMANS; INTERLEUKIN-23; MALE; MICE; NEOPLASM METASTASIS; PHOSPHORYLATION; SIGNAL TRANSDUCTION; STAT5 TRANSCRIPTION FACTOR; SUPPRESSOR OF CYTOKINE SIGNALING PROTEINS;

EID: 84904679757     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgu017     Document Type: Article

References (29)

1. Hue, S. et al. (2006) Interleukin-23 drives innate and T cell-mediated intestinal inflammation. J. Exp. Med., 203, 2473-2483.
2. Kullberg, M.C. et al. (2006) IL-23 plays a key role in Helicobacter hepaticus-induced T cell-dependent colitis. J. Exp. Med., 203, 2485-2494.
3. Yen, D. et al. (2006) IL-23 is essential for T cell-mediated colitis and promotes inflammation via IL-17 and IL-6. J. Clin. Invest., 116, 1310-1316.
4. Center, M.M. et al. (2009) Worldwide variations in colorectal cancer. Cancer J. Clin., 59, 366-378.
5. Lan, F. et al. (2011) IL-23/IL-23R: potential mediator of intestinal tumor progression from adenomatous polyps to colorectal carcinoma. Int. J. Colorectal Dis., 26, 1511-1518.
6. Oppmann, B. et al. (2000) Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12. Immunity, 13, 715-725.
7. Lankford, C.S. et al. (2003) A unique role for IL-23 in promoting cellular immunity. J. Leukoc. Biol., 73, 49-56.
8. Langowski, J.L. et al. (2006) IL-23 promotes tumour incidence and growth. Nature, 442, 461-465.
9. Fukuda, M. et al. (2010) IL-23 promotes growth and proliferation in human squamous cell carcinoma of the oral cavity. Inta. J. Oncol., 36, 1355-1365.
10. Paradowska, G.A. et al. (2011) IL-23 in the pathogenesis of rheumatoid arthritis. Scadn. J. Immunol., 71, 134-145. doi:10.1111/j.1365-3083.2009.02361.x.
11. Minamoto, S. et al. (1997) Cloning and functional analysis of new members of STAT induced STAT inhibitor (SSI) family: SSI-2 and SSI-3. Biochem. Biophys. Res. Commun., 237, 79-83.
12. Li, Y. et al. (2012) IL-6-induced DNMT1 activity mediates SOCS3 promoter hypermethylation in ulcerative colitis-related colorectal cancer. Carcinogenesis, 33, 1889-1896. doi:10.1093/carcin/bgs214. Epub 27 June 2012.
13. Jian, L. et al. (2012) Interleukin 23 promotes hepatocellular carcinoma metastasis via NF-kappa B induced matrix metalloproteinase 9 expression. PLoS One, 7, e46264. doi:10.1371/journal.pone.0046264.
14. Michele, W.L.T. et al. (2011) Anti-IL-23 monoclonal antibody synergizes in combination with targeted therapies or IL-2 to suppress tumor growth and metastases. Cancer Res., 71, 2077-2086. doi:10.1158/0008-5472. CAN-10-3994.
15. Li, J. et al. (2013) Interleukin 23 regulates proliferation of lung cancer cells in a concentration-dependent way in association with the interleukin-23 receptor. Carcinogenesis, 34, 658-666. doi:10.1093/carcin/bgs384.
16. Grivennikov, S.I. et al. (2012) Adenoma-linked barrier defects and microbial products drive IL-23/IL-17-mediated tumour growth. Nature, 491, 254-258.
17. Suzuki, H. et al. (2012) IL-23 directly enhances the proliferative and invasive activities of colorectal carcinoma. Oncol. Lett., 4, 199-204.
18. Chan, J.R. et al. (2006) IL-23 stimulates epidermal hyperplasia via TNF and IL-20R2-dependent mechanisms with implications for psoriasis pathogenesis. J. Exp. Med., 203, 2577-2587.
19. Kaiga, T. et al. (2007) Systemic administration of IL-23 induces potent antitumor immunity primarily mediated through Th1-type response in association with the endogenously expressed IL-12. J. Immunol., 178, 7571-7580.
20. Cocco, C. et al. (2010) Interleukin-23 acts as antitumor agent on childhood B-acute lymphoblastic leukemia cells. Blood, 116, 3887-3898.
21. Gu, L. et al. (2010) Transcription factor Stat3 stimulates metastatic behavior of human prostate cancer cells in vivo, whereas Stat5b has a preferential role in the promotion of prostate cancer cell viability and tumor growth. Am. J. Pathol., 176, 1959-1972. doi:10.2353/ajpath.2010.090653
22. Shen, H.B. et al. (2013) CXCR4-mediated Stat3 activation is essential for CXCL12-induced cell invasion in bladder cancer. Tumour Biol., 34, 1839-1845.
23. Zizi-Sermpetzoglou, A. et al. (2012) Expression of pSTAT3 in human colorectal carcinoma: correlation with clinico-pathological parameters. J. BUON., 17, 691-694.
24. Sultan, A.S. et al. (2005) Stat5 promotes homotypic adhesion and inhibits invasive characteristics of human breast cancer cells. Oncogene, 24, 746-760.
25. Wilop, S. et al. (2011) Methylation-associated dysregulation of the suppressor of cytokine signaling-3 gene in multiple myeloma. Epigenetics, 6, 1047-1052.
26. Pierconti, F. et al. (2011) Epigenetic silencing of SOCS3 identifies a subset of prostate cancer with an aggressive behavior. Prostate, 71, 318-325.
27. Dhar, K. et al. (2013) SOCS3 promotor hypermethylation and STAT3-NF-κB interaction downregulate SOCS3 expression in human coronary artery smooth muscle cells. Am. J. Physiol. Heart Circ. Physiol., 304, H776-H785.
28. Stevenson, N.J. et al. (2010) Suppressor of cytokine signalling (SOCS) 1 and 3 enhance cell adhesion and inhibit migration towards the chemokine eotaxin/CCL11. FEBS Lett., 584, 4469-4474.
29. Nakagawa, T. et al. (2008) Decreased expression of SOCS-3 mRNA in breast cancer with lymph node metastasis. Oncol. Rep., 19, 33-39.